NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the company’s lead compound, NOV-002, which is currently in a pivotal Phase 3 trial for non-small cell lung cancer and Phase 2 trials for other oncology indications, has been accepted into the National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) “Radiation/Nuclear Medical Countermeasures Product Development Program”.
